Cargando…
Transient Myopericarditis Following Vaccination for COVID-19
Clinical trials of the messenger ribonucleic acid (mRNA)-1273 vaccine developed by Moderna proved excellent safety and efficacy for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) prevention. However, the Centers for Disease Control and Prevention (CDC) has been investigating cases of m...
Autores principales: | Gill, Jashan, Mallari, Arvin Junn P., Zahra, Farah |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elmer Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8913003/ https://www.ncbi.nlm.nih.gov/pubmed/35317093 http://dx.doi.org/10.14740/jmc3876 |
Ejemplares similares
-
A case of myopericarditis following administration of the Pfizer COVID-19 vaccine
por: Morton, Zoey, et al.
Publicado: (2022) -
COVID-19 Vaccination-Induced Myopericarditis: An Imager’s Perspective
por: Bews, Hilary, et al.
Publicado: (2022) -
Acute Myopericarditis after COVID-19 Vaccine in Teenagers
por: Ambati, Shashikanth, et al.
Publicado: (2021) -
Recurrence of Myopericarditis Following mRNA COVID-19 Vaccination in a Male Adolescent
por: Umei, Tomohiko C., et al.
Publicado: (2021) -
Myopericarditis in a Young Adult Secondary to COVID-19 Vaccination
por: Walters, Corbin G., et al.
Publicado: (2021)